WO2002087625A1 - Composite oncolytic herpes virus vectors - Google Patents

Composite oncolytic herpes virus vectors Download PDF

Info

Publication number
WO2002087625A1
WO2002087625A1 PCT/IL2002/000345 IL0200345W WO02087625A1 WO 2002087625 A1 WO2002087625 A1 WO 2002087625A1 IL 0200345 W IL0200345 W IL 0200345W WO 02087625 A1 WO02087625 A1 WO 02087625A1
Authority
WO
WIPO (PCT)
Prior art keywords
derived
hsv
amplicon
individual
pharmaceutical composition
Prior art date
Application number
PCT/IL2002/000345
Other languages
English (en)
French (fr)
Inventor
Niza Frenkel
Original Assignee
Ramot At Tel-Aviv University Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv University Ltd. filed Critical Ramot At Tel-Aviv University Ltd.
Priority to EP02766686A priority Critical patent/EP1406668A1/en
Priority to US10/476,451 priority patent/US8216564B2/en
Priority to JP2002584967A priority patent/JP2004529158A/ja
Publication of WO2002087625A1 publication Critical patent/WO2002087625A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention concerns Herpes Simplex Virus (HSV) derived vectors and use thereof in the treatment of malignant diseases.
  • HSV Herpes Simplex Virus
  • HSV-1 and HSV-2 are typically induced to express suicidal genes destined to destroy the cell prior significant viral replication.
  • the virus undertakes an immediate counter attack by expressing the virion host shutoff (vhs) (UL41) gene - a 58 kDa structural component of the HSV-1 virion with a powerful mRNA destabilization/degradation activity.
  • vhs virion host shutoff
  • the vhs protein is shed into the cellular cytoplasm upon viral uncoating during viral entry into the cells (Read and Frenkel, 1983; Kwong et al. 1988; Kwong and Frenkel, 1987).
  • the vhs protein counteracts the cells' suicidal functions by immediate destabilization/ degradation of the infected cell mR As, including house keeping genes and stress related suicidal genes induced post viral infection and may encode anti apoptotic genes. In consequence of the mRNA degradative activity host cell protein synthesis is shutoff, the suicidal proteins are not produced and the cells survive for a certain period of time, allowing viral replication before death of the target cell.
  • HSV-1 mutants carrying a mutation in the vhs gene have been developed. Whereas wild type HSV-1 infection is accompanied by host mRNA degradation HSV mutants which are deficient in the virion host shut-off (vhs) function ( "vhsl mutants”) allow continued cell protein synthesis.
  • vhs virion host shut-off
  • UL41NHB was developed which infection into cells was shown to be attenuated in its ability to replicate and reactivate from latency (Leib, D., 1997).
  • HSV derived amplicons comprising at least one inserted gene under control of a promoter in association with helper HSV have been disclosed (Spaete and Frenkel, 1982, Frenkel et al., 1994,Vlazny, D.A. etal, 1981).
  • the associated helper virus is of a restricted replication competence in a normal host cell (Efstathiou S. et al, 1999).
  • the recombinant HSV vectors are modified to target and infect a selected cell type (Spear, M.A. 2000). The incidence of brain tumors is estimated to be 5-14.1 per 100,000.
  • Gliomas account for 40-60% of the primary tumors, 75% of which are malignant. Gliomas are the most common primary tumor arising in the human brain. Malignant gliomas account for 30% of primary brain tumors in adults, and are divided by grade into two categories, anaplastic astrocytoma and glioblastoma. The estimated incidence of malignant glioma in the United States is 14.7 per 100,000, representing approximately 10,000-15,000 new cases annually. Despite improved aggressive surgical therapy, radiotherrapy and chemotherapy, malignant gliomas are almost always fatal; the overall 5 year survival rate for glioblastoma, the most malignant glioma, is less than 5.5% and the median survival is approximately 52 weeks. These figures have remained virtually unchanged over the past three decades. Treatment of systemic tumors often fails because of development of central nervous system metastases. The advanced stage indicates no curability. Most gliomas have poor prognosis without any completely effective treatment
  • HSV viral vectors were evaluated for their efficacy and safety in clinical use in humans.
  • HSV derived vectors comprising HSV mutant viruses deficient in the gene encoding the 34.5 protein (a major determinant of neuropathology) were tested in patients with relapsed glioma.
  • This mutant is a mutli-mutated conditionally replicating HSV vector termed "G207" which has deletions of both 34.5 loci and in the ICP6 (ribonucleotide reductase (RR)) which is required for replication in non-dividing cells (Rabkin, S. et al 2000).
  • ICP6 ribonucleotide reductase
  • the G207 mutant is now being tested in a Phase I Clinical Trial for recurrent glioblastoma in which it has been shown to be non toxic and without serious adverse events, but its efficacy has not yet been demonstrated.
  • antineoplastic genes specifically cytokine genes
  • HSV type 1 thymidine kinase and gancyclovir gene therapy was evaluated as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiform (Ranov, N.G., 2000).
  • untreated glioblastoma multiform received either standard surgical and radiotherapy or standard therapy plus adjuvant gene therapy during surgery.
  • Clinical safety of the treatment was determined and was comparable in both groups but there were no significant clinical differences between gene therapy and control patients.
  • HSV derived viral oncolytic vectors having high efficacy for treatment of human tumors yet maintaining their safety are desired.
  • HSV derived vector for the treatment of a malignant disease
  • the HSV-derived vector of the invention comprises two main components: one component which is a defective viral genome with multiple reiterations of amplicon type repeat units each carrying inducible toxic genes with cell destructive capabilities (“the amplicon”) and as a second component an HSV mutant helper virus which is incapable of replication in non-dividing cells or at least has a significantly low replication capacity in such cells (“the helper virus”).
  • the helper virus an HSV mutant helper virus which is incapable of replication in non-dividing cells or at least has a significantly low replication capacity in such cells.
  • the helper virus is mutated in the virion host shut-off (vhs- UL41) genes.
  • the helper virus is double mutated both in the vhs gene as well as in the ribonucleotide reductase (RR) genes.
  • the dual viral arms of such a vector substantively enhance the efficacy of the vector while maintaining its safety.
  • the dual components of the vector of the invention which attack the target malignant cell both by effective expression of cytotoxic foreign genes on the amplicon which are expressed in many copies in a short period of time as well as by the ability of the mutated helper to drive the cell to cell death (apparently by inducing apoptosis), substantively enhance the efficacy of the vector while maintaining its safety.
  • the term "enhanced efficacy” should be understood to mean an efficacy which is higher than the efficacy of only one component of the vector (i.e. the amplicon comprising the toxic gene or helper vector).
  • a pharmaceutical composition for use in the treatment of a solid tumor in an individual comprising an effective amount of an HSV derived amplicon defective viral genome carrying at least one toxic foreign gene and an HSV-derived mutant helper virus and a pharmaceutically acceptable carrier, excipient or diluent.
  • the term "effective amount” relates to an amount of each of the HSV derived viral components which will, upon administration to the individual, achieve the desired therapeutic effect. With regards to the amplicon, an effective amount will be such which results in a desired amount of expression of the foreign toxic gene in a short period of time.
  • the effective amount of the helper component will be such that enhances the effect of the amplicon (by providing the necessary functions for gene expression) and preferably an amount which renders the helper virus cytotoxic to the cell. Wherein the helper virus is the vhs mutant, the effective amount will be such which leads to death of the target cell.
  • the defective genomes are engineered to carry foreign toxic genes.
  • the term "foreign toxic genes" relates to genes which are not naturally expressed by the target cells and are designed to destroy the cells in a controlled fashion. Any such toxin gene may be used in accordance with the invention, and the gene may be chosen by a person versed in the art on the basis of the kind of tumor to be treated as well as additional factors.
  • An example of such toxic gene in an amplicon is the gene encoding the thymidine kinase (TK) which when expressed in the cells renders them sensitive to ganciclovir, producing complete inhibition of host DNA replication and the destruction of the dividing cells.
  • TK thymidine kinase
  • TNF tumor necrosis factor
  • TRAIL TNF related apoptosis inducing ligand
  • P53 P53
  • Such toxic genes can be put under the control of the Tet On system, allowing the expression of the toxic genes only when treated with tetracycline.
  • Other toxin genes may be constructed to be expressed under control of other suitable promoters or inducers.
  • the amplicon in accordance with the invention may also comprise a number of toxic genes under the control of one or more promoters.
  • Such toxic genes may also be constructed under control of cell or tissue specific promoters which are expressed only in the desired cell or tissue (e.g. a promoter which controls expression of a prostate specific antigen (PSA) only in prostate cells).
  • PSA prostate specific antigen
  • the invention also provides use of an HSV derived amplicon defective viral genome carrying at least one toxic foreign gene and an HSV-derived mutant helper virus for the preparation of a pharmaceutical composition for the treatment of a solid tumor in an individual.
  • the present invention provides a method for the treatment of an individual having a solid organ tumor comprising administration of an HSV derived viral vector comprising an effective amount of a combination of an HSV derived amplicon defective viral genome carrying at least one toxic foreign gene and an HSV-derived mutant helper virus.
  • the helper virus comprises a mutation in the vhs gene.
  • the mutant helper virus carries also a mutation in the RR genes.
  • treatment in accordance with the invention should be understood to mean any alleviation of a condition of a patient suffering from a solid tumor. Such alleviation may be a reduction in the size of the tumor , reduction in the rate of growth of the tumor, alleviation of tumor-related symptoms, prevention of metastasis, etc.
  • the helper virus in accordance with the invention is constructed to carry a mutated virion host shutoff (vhs) gene such a vector is at times referred to as "vhs mutant".
  • vhs mutant mutated virion host shutoff
  • the transcribed mRNA of the toxic gene carried by the amplicon component of the composite vector is not immediately disintegrated and inactivated (as in the case of the non-mutated vhs gene), thus enabling expression of the toxic gene and enhancement of the apoptopic effect of the vhs component, resulting in enhanced efficacy of the composite vector as a whole.
  • the helper virus in accordance with the invention may also comprise a mutation in the RR gene.
  • the RR enzyme is essential for viral replication in resting, non-dividing cells, whereas the virus can use the cellular RR which is active in growing cells.
  • the RR mutation has been introduced in the small RR subunit (I I 39 gene) of the enzyme. This renders it inactive.
  • the use of RR mutation has the vector safer for use in gene therapy, by not allowing any replicating virus to spread to neighboring normal cells.
  • the helper vector may contain the RR mutation alone or together with the mutant vhs.
  • the two components of the composite vector of the invention may either be obtained by infecting cells with the helper virus and transfecting the same cells with amplicon plasmids or, by dual transfection of cells with helper virus DNA and amplicon plasmid followed by repeated serial propogation of the virus and amplicon mixture to generate a stock of cells comprising both components which can be then administered to the individual.
  • the amplicon may first be grown in cells of a cell line which comprises non infectious vhs mutated HSV helper viruses lacking the Pac-1 and Pac-2 signals and thus not being able to be packaged. In this manner, it is possible to prepare large quantities of the amplicons ex vivo without infectious helper viruses, resulting in an amplicon packaged in the virions of the vhs mutant virus.
  • Such packaged amplicons are infectious, i.e. they can enter into the cells and introduce both the foreign cytotoxic genes as well as the vhs-1 mutant gene.
  • Such amplicons may be administered to the individual without a helper virus, i.e. both components of the vector of the invention will be present in the packaged amplicons.
  • the HSV derived, composite oncolytic vector of the invention has a wide host range including epithelial, fibroblastic and neuronal cells and thus is suitable for the treatment of various solid organ tumors such as, for example, brain malignancies including neuroblastoma and glioblastoma multiform, lung, pancreatic, kidney, colon and stomach cancers.
  • the vector will be administered to the individual by local injection directly into the tumor.
  • components of the vector may also be administered by other administration routes including systemically, intraveneously (i.v.), subcutaneously (s.c), intramuscular (i.m.), intraperitoneal (i.p.) or orally.
  • Such components will be prepared in any of the formulations known in the art suitable for the specific route of administration chosen by the person versed in the art.
  • the HSV derived composite vector of the invention will typically have the following characteristics: (Spaete and Frenkel, 1982, Frenkel et al, 1994) (i)
  • the HSV amplicon is a versatile vector which can target fibroblastic, epithelial and neuronal cells.
  • the system consists of a helper virus and constructed defective genomes, which contain multiple reiterations of the amplicon DNA sequences.
  • Two cis acting signals are required for amplicon propagation in the presence of a helper virus: a DNA replication origin and the cleavage packaging signals.
  • the amplicon can use either the OriS or the OriL replication origins.
  • the helper virus supplies, in trans, the DNA replication and packaging machinery including replication enzymes (e.g viral DNA polymerase, helicase, primase, ligase and DNA binding proteins) and the packaging functions, including the proteins and glycoproteins of the HSV virion.
  • replication enzymes e.g viral DNA polymerase, helicase, primase, ligase and DNA binding proteins
  • packaging functions including the proteins and glycoproteins of the HSV virion.
  • the long replicated DNA concatemers are cleaved during the packaging process.
  • the cleavage/packaging signals "pac-1" and "pac-2" are present in the a sequences.
  • the cleaved DNA molecules range in size from a single to multiple repeat units, corresponding in their overall size from the size of individual amplicons up to the intact HSV-1 genome (152kb). To determine the details of the cleavage/packaging process we have analyzed by pulse field electrophoresis the viral DNA molecules present in cells, which received different size amplicons.
  • the repeat units of the HSV-1 defective genomes can reach 17 kb in their size. Viral amplicons of larger size are randomly deleted in the process of DNA replication, until the repeat unit size reaches 17 kb (Kwong and Frenkel, 1985). Defective virus genomes containing repeats of sizes smaller than 17kb can be stable propagated in virus stocks for more than 50 sequential passages.
  • the HSV derived amplicon may also carry a marker gene which enables detection of the vector.
  • a marker gene may be any of the known marker genes such as, for example, the green fluorescence protein (GFP) marker genes.
  • GFP green fluorescence protein
  • the composite oncolytic HSV derived vector comprising the two above described components may be administered to an individual in combination with additional treatments or components.
  • One such component may, for example, be an additional viral vector comprising a gene encoding a peptide which enhances the immune activity of the treated individual.
  • An example of such a vector is one capable of infecting lymphotropic cells such as a herpes virus 6 (HHV-6) or HHV-7 derived amplicon (Romi et al, 1999) containing the "immunogenic" gene.
  • the immunogenic gene may for example be a gene which encodes for an interleukin such as IL-2, IL-4, IL-10 or Interferon and, upon administration, enhances the expression of such peptides in the cells.
  • the "immunogenic" vector may be administered in various combinations with the HSV- derived vectors.
  • the additional component may be administered to the individual by any of the administration routes described above and at various times before, during or after administration of the composite oncolytic HSV derived vector.
  • the present invention further provides a combination of two pharmaceutical compositions including a first pharmaceutical composition comprising an effective amount of an HSV derived defective viral amplicon genome carrying at least one toxic foreign gene together with an HSV-derived mutant helper vector and a second pharmaceutical composition comprising an effective amount of an viral derived amplicon carrying a gene encoding for a peptide capable of enhancing the immune system of the treated individual, the combination intended for administering to the individual for treatment of a solid tumor, in which treatment said second composition is administered at time T, said time T being before, during or after administration of said first pharmaceutical composition.
  • the above combination may be in the form of a package including said first and said second pharmaceutical compositions.
  • the invention further provides a method for the treatment of a solid tumor in an individual comprising administering to said individual an effective amount of a first pharmaceutical composition comprising an effective amount of an HSV derived defective viral amplicon genome carrying at least one toxic foreign gene together with an HSV-derived mutant helper vector and at time T before during or thereafter administering to said individual a second pharmaceutical composition comprising an effective amount of a viral derived amplicon carrying a gene encoding for a peptide capable of enhancing the immune system of the treated individual.
  • the invention further provides use of a first pharmaceutical composition comprising an effective amount of an HSV derived defective viral amplicon genome carrying at least one toxic foreign gene together with an HSV-derived mutant helper vector for the treatment of a solid tumor in an individual, which treatment includes administering to the individual said first composition and at a time T before, during or thereafter, administering to said individual a second pharmaceutical composition comprising an effective amount of a viral derived amplicon carrying a gene encoding for a peptide capable of enhancing the immune system of the treated individual.
  • kits comprising a a first pharmaceutical composition comprising an effective amount of an HSV derived defective viral amplicon genome carrying at least one toxic foreign gene together with an HSV- derived mutant helper vector and a second pharmaceutical composition comprising an effective amount of a viral derived amplicon carrying a gene encoding for a peptide capable of enhancing the immune system of the treated individual, together with directions for use.
  • the additional treatment administered to the treated individual may be any other treatment typically administered to individuals having a solid tumor, such as for example, treatments intended to enhance the level of immune response (e.g. Interferon) or treatment and targeting of the tumor cells such as radiation or chemotherapy.
  • treatments intended to enhance the level of immune response e.g. Interferon
  • treatment and targeting of the tumor cells such as radiation or chemotherapy.
  • FIG. 1 is a schematic representation showing an example of the two components of the composite oncolytic HSV-1 derived vector of the invention.
  • One component shown is an HSV-1 amplicon carrying multiple reiterations of at least one toxic gene and the second component is a mutant HSV-1 derived helper virus with replication capacity in dividing cells and carrying a mutation in the virion host shutoff (vhs) function which induces cellular suicidal death functions as well as a mutation in the ribonucleotide reductase (RR) gene.
  • vhs virion host shutoff
  • Fig. 2 is a schematic representation showing an example of one component of the composite oncolytic vector of the invention being an HSV-derived oncolytic HSV-1 amplicon carrying the p53, a viral origin of replication (ori) and packaging signals (pac).
  • HSV-derived oncolytic HSV-1 amplicon carrying the p53, a viral origin of replication (ori) and packaging signals (pac).
  • Fig. 3 is a schematic representation showing the replication of a vhs-1 mutant helper virus after infection into mouse cerebral granular neurons as compared to a wild type HSV (KOS) vector infected into such cells. The replication was measured at different multiplicities of infection (m.o.i.) and at different times after infection.
  • Fig. 4 is a graphic representation showing the viability of non infected mouse neuron cells (mock-control) and mouse neuron cells following infection with the vhs-1 mutant vector in different multiplicities of infection at different times after infection of the cells and as measured by the MTT assay.
  • Fig. 3 is a schematic representation showing the replication of a vhs-1 mutant helper virus after infection into mouse cerebral granular neurons as compared to a wild type HSV (KOS) vector infected into such cells. The replication was measured at different multiplicities of infection (m.o.i.) and at different times after infection.
  • Fig. 4 is a graphic representation showing the viability of non inf
  • FIG. 5 is a schematic representation showing the viability of neuron cells after infection of the cells with either a HSV derived vector (KOS) or a vhs-1 mutant vector at various times after infection of the cells and as measured by the trypan blue assay as compared to non infected (mock) control cells.
  • KOS HSV derived vector
  • Fig. 6 shows photographs of mouse neuronal cell cultures infected with the KOS or vhs-1 viral vectors at various times after infection and DAPI staining. Apoptosis is seen in the vhs-1 infected cells.
  • Fig. 7 is a schematic representation showing the percent of cell death of HI 299 human lung carcinoma cells infected with the vhs-1 mutant helper virus alone or in combination with a HSV-1 amplicon vector carrying the p53 gene.
  • the vectors were infected at a multiplicity of infection of 1 plaque fo ⁇ ning unit (pfu)/cell (Fig. 7A) and 10 pfu/cell (Fig. 7B) and the number of viable dead cells were determined at various times after infection by the trypan blue assay.
  • Fig. 8 is a schematic representation showing cell death of HI 299 human lung carcinoma cells after infection with an HSV derived vector carrying the 34.5 mutation alone or in combination with an HSV-1 derived amplicon comprising the p53 gene in a multiplicity of infection of 1 pfu/cell (Fig. 8A) or 3 pfu/cell (Fig. 8B) at various times after infection of the cells and as determined by the trypan blue assay.
  • Fig. 9 is a schematic representation showing the viability of HI 299 human lung carcinoma cells after infection with the doubly mutated HSV-1 vector carrying the 34.5 and vhs mutant genes in combination with an HSV-1 amplicon carrying the p53 cytotoxic gene at a multiplicity of infection of 1 pfu/cell (Fig. 9A) or 10 pfu/cell (Fig. 9B) at various times after infection of the cells and as determined by the trypan blue assay.
  • Cell cultures - Primary cultures highly enriched for cerebellar granular neurons were prepared from 8 days old BALB-C mice. Cultures were made f om mouse brains. The cells were trypsinized and plated on dishes coated with poly-L-lysine in standard medium (basal medium Eagle's, 10% fetal calf serum, 25 mM KC1, 2 mM glutamine, 50 ⁇ g/ml gentamycin and 250 ng/ml amphotericine B supplemented with 1 mg/ml glucose. Cytosine- ⁇ -arabinofuramoside (Ara-C) (10 ⁇ M) was added to the medium 18-22 h after plating to prevent replication of non neuronal cells.
  • Basal medium Eagle's, 10% fetal calf serum, 25 mM KC1, 2 mM glutamine, 50 ⁇ g/ml gentamycin and 250 ng/ml amphotericine B supplemented with 1 mg/ml glucose.
  • Viruses - HSV-1 (KOS) served as the wild type virus.
  • the virion associated host shutoff mutant was derived in our laboratory from -1 (KOS) by general BudR mutagenesis and selection of mutants which did not shutoff host protein synthesis in the presence of actinomycin D to reassure that this is a virion function brought into the cells within the infecting virions (Read and Frenkel, 1983).
  • Virus stocks were made with limited passaging, employing Vero cells at an input multiplicity of infection (m.o.i.) of 0.01 pfu/cells.
  • HSV infection of cerebellar granule cells - The granule neurons were infected four days after plating the neurons. The number of viable cells was determined each experiment, employing trypan blue exclusion assay. The neurons were washed twice with conditioned medium to remove the Ara-C and then exposed to the appropriate virus m.o.i., as stated in the text. Infection was in 199V medium with 1% fetal serum. The cells were infected for two hours at 37°C. The innoculum was then removed and conditioned medium added prior to further incubation at 37°C.
  • Assay of infectious virus yield - At different times p.i. the infected cerebellar granule neurons were harvested and disrupted by three cycles of freezing and thawing, to release the virus. Infectious virus was titered by plaque assays in Vero cells.
  • Trypan blue viability assay - Neuron survival was determined by trypan blue exclusion assay. Cells were incubated for 10 min in a solution of 0.1% of trypan blue in phosphate buffer saline (PBS), pH-7.4 and then washed twice with PBS. Three randomly chosen fields which contained approximately 500 cells each were analyzed by phase-contrast and bright field microscopy. Cells excluding the dark blue dye were counted as viable, whereas blue-stained cells were scored as dead.
  • PBS phosphate buffer saline
  • MTT assay - A modification of previously described procedure was used: neuronal cultures (in 96 well plates) were incubated for 60min. at 37°C with 0.5 mg/ml MTT in standard medium. The MTT solution was aspirated and the cells were lysed in 200 ml DMSO. The amount of MTT formazan was quantified by determining the absorbency at 490/690 in a Bio-tek microplate reader (Wiooski, VT, USA).
  • DNA staining with DAPI - Cells were grown on glass cover slip coated with poly- 1-lysin. The cells were infected. Upon completion of the experiments, the cells were washed with phosphate saline buffer pH-7.4 (PBS) and fixed for 10 min in 4% formaldehyde (in PBS). After fixation the neurons were washed with PBS, stained for 5 min with 10 ⁇ g/ml DAPI (4,6-diamino-2-phenylindol), and washed twice with PBS; a drop of either N-propyl gallat or glycerol was added to enhance fluorescence, which was detected by UV light microscopy.
  • PBS phosphate saline buffer pH-7.4
  • wt HSV-1 (KOS) and the vhs-1 mutant viruses in mouse cerebellar granule neurons
  • Fig. 3 compares infectious virus yield in the neuronal cells up to 48-hrs post infection (p.i.) with input m.o.i. of 0.1,1 and 10 PFU/cell. Titration of the resultant virus stocks was done in Vero cells. The results have shown that the wt virus replicated productively in the neuronal cells. Infectious virus yield was highest in the cultures infected with an input m.o.i. of O.lpfu /cell (1428 fold amplification of the input virus).
  • the vhs-1 mutant did not replicate well in the neuronal samples, with infectious virus yield corresponding to 2 fold-input virus in cells infected with 0.1 PFU/cell vhs-1 mutant virus and no amplification of virus in cells infected with 1 and 10 PFU/cell respectively. Based on the data it can be concluded that the vhs-1 mutant posses only limited capacity to replicate in the brain cells.
  • vhs function causes destabilization/degradation of host cell mRNAs it was of interest to determine whether the infected cells were induced to undergo into a programmed cell death, and whether the vhs-1 mutant was more toxic to the cerebellar granule neurons.
  • Duplicate 96 well cultures cultures of the purified cereberal neuron cultures were infected with HSV-1 (KOS), or the vhs-1 mutant viruses. Cell viability was measured by MTT formazan incorporation at 12, 24, 36 and 48 hrs p.i., quantified by 490/690 absorbency in Bio-tek microplate reader.
  • An exemplary experiment involved infection of 96 well monolayers of purified granular neurons cultures at input m.o.i. of 1, 5 and 10 PFU/cell of HSV-1 (KOS) or the vhs-1 mutant viruses. As shown in Fig. 4. Whereas the neuronal infection with the wt HSV-1 (KOS) did not cause apoptosis by 48 hrs p.i., the vhs-1 mutant virus infection was accompanied with pronounced (down to 50%) apoptosis.
  • neuronal viability was determined by trypan blue exclusion assay. Cells excluding the dark blue dye were counted as viable, whereas blue-stained cells were scored as dead. As shown in Fig. 5, whereas KOS virus infection at m.o.i. of 3 PFU/cell did not cause substantial cell death by 48 hrs p.i., close to 50 and 70 % death of neuronal cells have died in the vhs-1 infected cultures.
  • Fig. 6 shows that nuclei of uninfected granule neurons appeared uniform in size, with an oval shape, and were rather homogeneously stained with moderate intensity and spotted with glowing areas, typical of mouse cells. Twelve hours after exposure to KOS the cells appeared unchanged whereas in the cells exposed to vhs viruses, some neurons' nuclei lost their oval shape and appeared like bright round spots.
  • the vhs-1 mutant virus infection causes more pronounced apoptosis and earlier that the limited apoptosis caused by the wt virus.
  • the above results also show that wt virus inhibits host gene expression post infection by letting the vhs RNase start destabilization/ degradation of infected cell mRNAs including the host death genes induced in response to viral infection.
  • the cellular mRNAs are expressed efficiently in vhs-1 mutant virus infection, resulting in pronounced apoptosis.
  • cell survival was advantageous for virus replication and whereas wt virus which did not cause apoptosis replicated well in the cerebellar neurons the vhs-1 mutant, which kills the cell, did not replicate in mouse neurons even by 48 hours post infection.
  • HI 299 human lung carcinoma cell line cells were infected with HSV-1 mutants (exemplified by vhs-1, ⁇ 34.5 and the 34.5, vhs double mutant) at multiplicity of infection of 1 and 10 pfu/cell.
  • the helper virus In lung cells, the helper virus must carry a mutation which prevents its replication in order to be safe. The number of viable and dead cells were determined at 14, 24, 36, 48, 72 and 96 hours post infection by trypan blue assay.
  • the cells were incubated 1 min. in a solution containing 0.1% of trypan blue in phosphate buffer saline. Then 500 cells were counted by bright field microscope. Cells excluding the blue dye were counted as viable, whereas blue stained cells were scored as dead.
  • HSV-1 amplicons containing the thymidine kinase (tk) gene were constructed.
  • the amplicon is infected into various cells and tk gene expression in the in infected cells is evaluated by Western Blot analysis as described above.
  • gancyclovir induced death of the cells infected with the tk comprising amplicon alone or in combination with an HSV helper virus containing a mutated hvs gene is evaluated using the trypan blue or MTT assays as described above.
  • TNF gene in various infected cells as well as cell death of cells infected with the TNF comprising amplicon alone or in combination with an HSV derived helper vector containing a mutated hvs gene is evaluated as described above.
  • mice are injected subcutaneously with cells of a human glioblastoma cell line. At various stages of growth of the tumors, the mice are divided into the following groups:
  • mice receiving injections of the vhs-1 mutant HSV vector (b) mice receiving injections of the vhs-1 mutant HSV vector; (c) mice receiving injections of a combination of the HSV amplicon carrying one or more toxic genes and the vhs-1 mutant HSV helper virus;
  • mice receiving injections of the pure HSV amplicon devoid of infectious helper virus but carrying one or more toxic genes and the vhs-1 mutant protein in the virion encapsulating the amplicon (grown in cells comprising a pac- 1 , pac-2 deleted and vhs mutant helper virus);
  • mice receiving each of the treatments of (a) - (d) together with a systemic infection of an HW-6 or HW-7 derived amplicon containing an IL-2 encoding gene at various times before, together with or after the injection of the HSV vectors.
  • the viral vectors are injected directly into the tumors of the mice and the development of the tumors in each of the groups is determined at various times after injection and compared to the development of the tumors in the control group.
  • the above-mentioned vectors are injected into tumors developed from pancreatic malignant cells or long malignant cells in nude mice, as another example to highly malignant tumors within internal organs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/IL2002/000345 2001-05-02 2002-05-02 Composite oncolytic herpes virus vectors WO2002087625A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02766686A EP1406668A1 (en) 2001-05-02 2002-05-02 Composite oncolytic herpes virus vectors
US10/476,451 US8216564B2 (en) 2002-05-02 2002-05-02 Composite oncolytic herpes virus vectors
JP2002584967A JP2004529158A (ja) 2001-05-02 2002-05-02 混成殺腫瘍ヘルペスウイルスベクター

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28771701P 2001-05-02 2001-05-02
US60/287,717 2001-05-02

Publications (1)

Publication Number Publication Date
WO2002087625A1 true WO2002087625A1 (en) 2002-11-07

Family

ID=23104029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000345 WO2002087625A1 (en) 2001-05-02 2002-05-02 Composite oncolytic herpes virus vectors

Country Status (3)

Country Link
EP (1) EP1406668A1 (enrdf_load_stackoverflow)
JP (1) JP2004529158A (enrdf_load_stackoverflow)
WO (1) WO2002087625A1 (enrdf_load_stackoverflow)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064765A3 (en) * 2003-01-23 2005-04-28 Univ Rochester Herpesvirus amplicon particles
US7361354B1 (en) 1999-11-25 2008-04-22 Viralytics Limited Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses
US7485292B2 (en) 2002-12-18 2009-02-03 Viralytics Limited Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
US8119118B2 (en) 2000-11-29 2012-02-21 University Of Rochester Helper virus-free herpesvirus amplicon particles and uses thereof
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007394A1 (en) * 1997-08-12 1999-02-18 Georgetown University Use of herpes vectors for tumor therapy
WO2000008191A2 (en) * 1998-07-31 2000-02-17 Biovex Limited Herpes virus vectors for dendritic cells
WO2000065078A1 (en) * 1999-04-26 2000-11-02 Cedars-Sinai Medical Center A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007394A1 (en) * 1997-08-12 1999-02-18 Georgetown University Use of herpes vectors for tumor therapy
WO2000008191A2 (en) * 1998-07-31 2000-02-17 Biovex Limited Herpes virus vectors for dendritic cells
WO2000065078A1 (en) * 1999-04-26 2000-11-02 Cedars-Sinai Medical Center A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURTON E A ET AL: "MULTI-MODAL COMBINATION GENE THERAPY FOR MALIGNANT GLIOMA USING REPLICATION-DEFECTIVE HSV VECTORS", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 6, no. 7, 1 April 2001 (2001-04-01), pages 347 - 356, XP001057064, ISSN: 1359-6446 *
JACOBS A ET AL: "HSV-1-BASED VECTORS FOR GENE THERAPY OF NEUROLOGICAL DISEASES AND BRAIN TUMORS: PART II. VECTOR SYSTEMS AND APPLICATIONS", NEOPLASIA, DOYMA, BARCELONA,, ES, vol. 1, no. 5, November 1999 (1999-11-01), pages 402 - 416, XP000929617, ISSN: 0212-9787 *
KAGAWA SHUNSUKE ET AL: "Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 8, 15 April 2001 (2001-04-15), pages 3330 - 3338, XP002196458, ISSN: 0008-5472 *
MARKERT J M ET AL: "Genetically engineered human herpes simplex virus in the treatment of brain tumours.", HERPES: THE JOURNAL OF THE IHMF. ENGLAND MAR 2001, vol. 8, no. 1, March 2001 (2001-03-01), pages 17 - 22, XP002212552, ISSN: 0969-7667 *
ROSENFELD M R ET AL: "Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line.", NEUROLOGY, vol. 45, no. 8, 1995, pages 1533 - 1539, XP001099030, ISSN: 0028-3878 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361354B1 (en) 1999-11-25 2008-04-22 Viralytics Limited Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses
US8722036B2 (en) 1999-11-25 2014-05-13 Viralytics Limited Methods for treating malignancies using coxsackieviruses
US8119118B2 (en) 2000-11-29 2012-02-21 University Of Rochester Helper virus-free herpesvirus amplicon particles and uses thereof
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
US7485292B2 (en) 2002-12-18 2009-02-03 Viralytics Limited Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004064765A3 (en) * 2003-01-23 2005-04-28 Univ Rochester Herpesvirus amplicon particles
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Also Published As

Publication number Publication date
EP1406668A1 (en) 2004-04-14
JP2004529158A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
JP6644378B2 (ja) ウイルス株
Yoon et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
KR101177659B1 (ko) 바이러스 벡터
Benencia et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma
EP1150696B1 (en) Genetically engineered herpes virus for the treatment of tumours
AU2001226951A1 (en) Virus strains for the oncolytic treatment of cancer
JP5070583B2 (ja) ヒトグリオーマ治療に有用なリコンビナントｈｓｖ
EP1173598A1 (en) A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
US8216564B2 (en) Composite oncolytic herpes virus vectors
EP1406668A1 (en) Composite oncolytic herpes virus vectors
JP2003508055A (ja) ヘルペスγ３４．５遺伝子発現の細胞特異的および／または腫瘍特異的プロモーター再標的化
AU725557B2 (en) Avirulent herpetic viruses useful as tumoricidal agents and vaccines
Stevenson et al. Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells
WO2005024016A1 (ja) ヒトグリオーマ治療に有用な変異ｈｓｖベクター

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10476451

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002584967

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002766686

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002766686

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002766686

Country of ref document: EP